Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
- New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to standard of care alone1
- US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to 177Lu-PSMA-617; Submission to FDA and European Medicines Agency on track for 2H21
- Novartis committed to reimagining prostate cancer with targeted radioligand therapy; two Phase III studies with 177Lu-PSMA-617 in earlier lines of treatment ongoing with goal to investigate earlier stages of disease
Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone. Many patients with mCRPC live with reduced physical functioning as well as significant pain2,3. This data from a quality of life assessment of the VISION trial, referred to as HRQoL, showed delayed worsening of these difficult to bear symptoms in the 177Lu-PSMA-617 plus standard of care arm compared to standard of care alone arm. No new or unexpected safety concerns, including changes in creatinine clearance, were noted1. These results will be presented at the European Society for Medical Oncology (ESMO) Congress, 17-21 September 2021.
HRQoL ad hoc analysis showed that the 177Lu-PSMA-617 plus standard of care arm resulted in an estimated 54% risk reduction in the worsening of HRQoL (measured by Functional Assessment of Cancer Therapy – Prostate (FACT-P) scale) from baseline (hazard ratio: 0.46 with 95% confidence interval (CI): (0.35, 0.61)) compared to the standard of care only arm1. In addition, 177Lu-PSMA-617 plus standard of care also resulted in an estimated 55% risk reduction of worsening of pain intensity (measured by Brief Pain Inventory – Short Form (BPI-SF) scale) from baseline (hazard ratio: 0.45 with 95% (CI): (0.33, 0.60)) compared to the standard of care only arm1.
“Patients with mCRPC suffer from many complications associated with advanced disease that can impact their quality of life2,3,” said Jeff Legos, Global Head of Oncology Development, Novartis. “These new data emphasize the potential impact on quality of life that investigational 177Lu-PSMA-617 may provide as a potential new treatment option, beyond previously reported improvements in overall survival and radiographic progression-free survival4.”
Two additional studies with 177Lu-PSMA-617 radioligand therapy in earlier lines of treatment for metastatic prostate cancer are ongoing, investigating potential clinical utility in the mCRPC pre-taxane setting (PSMAfore) and in the metastatic hormone-sensitive setting (PSMAddition). Novartis is also evaluating opportunities to investigate 177Lu-PSMA-617 radioligand therapy in earlier stages of prostate cancer.
About Advanced Prostate Cancer
Prostate cancer is a form of cancer that develops in the prostate gland, a small walnut shaped gland in the pelvis of men. In castration resistant prostate cancer (CRPC), the tumor shows signs of growth, such as rising Prostate Specific Antigen (PSA) levels, despite the use of hormone treatments that lower testosterone5. In metastatic CRPC (mCRPC), the tumor spreads to other parts of the body, such as neighboring organs or bones and remains unresponsive to hormone treatment5. The five-year survival rate for patients with metastatic prostate cancer is approximately 30%6.
About Phenotypic Precision Medicine in Advanced Prostate Cancer
Despite advances in prostate cancer care, there is a high unmet need for new targeted treatment options to improve outcomes for patients with mCRPC. More than 80% of prostate cancer tumors highly express a phenotypic biomarker7 called Prostate Specific Membrane Antigen (PSMA) 8-10,11,12, making it a promising diagnostic (through positron emission tomography (PET) scan imaging) and potential therapeutic target for radioligand therapy13. This differs from ‘genotypic’ precision medicine which targets specific genetic alterations in cancer cells7.
177Lu-PSMA-617 is an investigational PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. It is a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle)14-16. After administration into the bloodstream, 177Lu-PSMA-617 binds to prostate cancer cells that express PSMA17, a transmembrane protein, with high tumor-to-normal tissue uptake14,18,19. Once bound, emissions from the radioisotope damage tumor cells, disrupting their ability to replicate and/or triggering cell death20-22. The radiation from the radioisotope works over very short distances to limit damage to surrounding cells13,14,18.
VISION is an international, prospective, randomized, open-label, multicenter, phase III study to assess the efficacy and safety of 177Lu-PSMA-617 (7.4 GBq administered by intravenous infusion every 6 weeks for a maximum of 6 cycles) plus investigator-chosen standard of care in the investigational arm, versus standard of care in the control arm4. Patients with PSMA PET-scan positive mCRPC, and progression after prior taxane and androgen receptor pathway inhibitors, were randomized in a 2:1 ratio in favor of the investigational arm4. The study met both alternate primary endpoints of radiographic progression free survival and overall survival; secondary endpoints were also met4. The study enrolled 831 patients4.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact email@example.com
1. Novartis data on File
2. Kuppen MCP, Westgeest HM, van den Eertwegh AJM et al. Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. Clin Genitourin Cancer 2020;18(3):e233–e253
3. Sullivan PW, Mulani PM, Fishman M et al. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer Qual Life Res. 2007;16:571–575
4. Sartor O, J. de Bono KN, Chi K, et al Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322
5. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180–92
6. SEER. Cancer stat facts: prostate cancer July 2021. [https://seer.cancer.gov/statfacts/html/prost.html]
7. Sant GR, Knopf KB, Albala DM. Live-single-cell phenotypic cancer biomarkers-future role in precision oncology? NPJ Precision Oncology 2017;1(1):21
8. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol 2018;8:623
9. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82(11):2256–61
10. Pomykala KL, Czernin J, Grogan TR, et al. Total-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines. J Nucl Med 2020;61(3):405–11
11. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011;71(3):281–8
12. Hope TA, Aggarwal R, Chee B, et al. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med 2017;58(12):1956–61
13. Hofman MS, Violet J, Hicks RJ et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19(6):825–33
14. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med 2016;57(8):1170–6
15. Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012;23(4):688–97.
16. Benešová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 2015;56(6):914–20
17. Haberkorn U, Eder M, Kopka K, et al. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin Cancer Res 22(1):9-15.2016
18. Violet J, Jackson P, Ferdinandus J et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med 2019;60(4):517–23
19. Current K, Meyer C, Magyar CE et al. Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intra-tumoral PSMA heterogeneity. Clin Cancer Res 2020;26(12):2946–55.
20. Kassis A. Therapeutic Radionuclides: Biophysical and Radiobiologic Principles. Semin Nucl Med. 2008; 38(5): 358–366
21. Fendler W, Stuparu A, et al. Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. J Nucl Med 2017; 58: 1786–1792
22. Ruigrok E, van Vliet N, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020; 48: 1339-1350
# # #
Novartis Media Relations
|Anja von Treskow|
Novartis Global Media Relations
+41 79 392 8697
Novartis US External Engagement
+1 862 579 8456
Advanced Accelerator Applications, a Novartis Company
+1 917 375 2935
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 345 4440|
|Thomas Hungerbuehler||+41 61 324 8425||Alina Levchuk||+1 862 778 3372|
|Isabella Zinck||+41 61 324 7188||Parag Mahanti||+1 973-876-4912|
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Jotul Holdings SA to redeem its outstanding up to NOK 400,000,000 senior secured floating rate bonds with ISIN NO001081574919.10.2021 20:00:00 CEST | Press release
Jotul Holdings SA hereby refers to its outstanding up to NOK 400,000,000 senior secured floating rate bonds with ISIN NO0010815749 (the "Bonds") and to the terms and conditions of the Bonds (the "Terms and Conditions"). Reference is further made to a call notice dated 28 September 2021, in which Jotul Holdings SA informed the holders of the Bonds that it was exercising its option to redeem all outstanding Bonds in full pursuant to Clause 9.3 (Voluntary total redemption (call option)) of the Terms and Conditions (the "Call Notice") on 25 October 2021 (the "Redemption Date"). Jotul Holdings SA's obligation to redeem the Bonds on the Redemption Date was conditional upon Jøtul AS fulfilling the conditions precedent for disbursement of the net proceeds from its bonds issued 6 October 2021, which are, among other things, to be applied towards financing the redemption of the Bonds by way of repayment of shareholder loans provided by Jotul Holdings SA (the "Financing Condition"). Jotul Holding
Greenland Resources Appoints Jens Moberg as Senior Advisor19.10.2021 15:57:02 CEST | Press release
TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Greenland Resources Inc. (NEO:MOLY, FSE:2LF) (“Greenland Resources” or the “Company”) is pleased to announce that it has created a European Advisory Board with the objective of providing strategic and technical input to corporate decision-making in respect of relevant stakeholders in the European industry ecosystem, with particular reference to the development of the Malmbjerg molybdenum deposit in east Greenland. To this extent, Mr. Jens Moberg will join as Senior Advisor. Jens has over twenty-five years of experience in international executive positions. Currently, he is the Chairman of the Board of Grundfos, a leading pump and water technology company with over 19,000 employees represented in more than 60 countries. He also acts as Member of the Board of Kirk Kapital A/S, a family owned financial investment firm with a heritage that stretches back to the world-famous LEGO name; and as a member of The Poul Due Jensen Foundation Board. To nam
VoltH2 Expands Management Team19.10.2021 15:50:29 CEST | Press release
JERSEY CITY, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Vision Hydrogen Corporation (OTCQB:VIHD) (the “Company”) is pleased to announce that VoltH2, a Europe-based developer of green hydrogen production infrastructure projects that is 15.9% owned by the Company, has expanded its management team. VoltH2 continues to make significant progress in realizing its objectives and has made a number of strategic hires, increasing its core team of highly experienced commercial and engineering professionals to 10 individuals, with a plan to double the team headcount by Q2 2022 as the pace of business continues to increase. Since commencing operation in early 2020, VoltH2 has been successfully executing on its mission to design, develop and build scalable hydrogen production facilities at multiple strategic locations in Western Europe. Deploying only proven and commercial technologies in partnership with established energy-industry participants, VoltH2 has been awarded permits for
Benjamin Hill Updates on Planned Inaugural Drill Program With Outline of Prospective Targets19.10.2021 13:30:00 CEST | Press release
VANCOUVER, British Columbia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Benjamin Hill Mining Corp. (CSE: BNN) (OTCBB: BNNHF) (“BHM” or the “Company”) Benjamin Hill Mining Corp. is pleased to announce that drill locations have been finalized for the upcoming inaugural drill program on our Sonora Gold property in Sonora, Mexico. The objective of the drill program is to test the continuity of high-grade mineralized shoots nested within vein and vein breccia sets. The program has been specifically designed to better understand the behavior of mineralization at depth and test structures that are thought to be open down dip and on strike. A total of 15 drill holes are initially planned, spread across the three most prospective exploration areas on the property. Targets and scale of the program are subject to change at the direction of management in collaboration with the experienced geological team. Greg Bronson, President of Benjamin Hill Mining Corp. states: "Everyone at Benjamin Hill is anticipati
Mandalay Resources Corporation Announces Production and Sales Results for the Third Quarter of 202119.10.2021 13:30:00 CEST | Press release
TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) announced today its production and sales results for the third quarter of 2021. Third Quarter 2021 Production Highlights: Consolidated saleable gold equivalent production of 33,121 ounces – highest quarterly result since Q4 2017;Consolidated 29,752 ounces of gold equivalent sold – highest quarterly amount in four years;Costerfield’s highest ever quarterly saleable gold equivalent production of 18,946 ounces; andCerro Bayo produced 2,925 ounces of gold equivalent. The Company expects Cerro Bayo’s overall contribution to be 9,000 – 10,000 ounces of gold equivalent by year end. Based on year-to-date production results, Mandalay anticipates that consolidated 2021 saleable production (not including production from Cerro Bayo) will be at the higher end of the previously provided production guidance range of the 105,000 – 117,000 ounces of gold equivalent. Dominic D
EthosEnergy CEO Ana Amicarella recognized as Top Executive for 202119.10.2021 13:00:00 CEST | Press release
San Antonio, Texas, Oct. 19, 2021 (GLOBE NEWSWIRE) -- San Antonio, Texas – EthosEnergy’s CEO, Ana Amicarella has been recognized as Top Executive of the Year during the Experience Power conference hosted by Power magazine. Power magazine honored innovative leaders from the power generation industry during an awards ceremony at the Experience Power conference last night. A worldwide call for nominations went out and submissions were narrowed down to a shortlist of award-worthy contenders into 15 categories. Ana Amicarella, CEO of EthosEnergy said: “I am honored to have won this award. But most of all, I am proud of everything our team has achieved over the last year despite challenging conditions.” Faced with outage cancellations and postponements due to COVID-19, and a depressed oil and gas sector, EthosEnergy’s reaction was to restructure the business to better align with customers and market dynamics. Ana Amicarella was appointed CEO in December 2019 with a mission to take EthosEnerg
Fobi Corporate Update Includes New Revenue Deals, Key Product Launches, New Verticals, Continued Partner Integrations And Further M&A Success And Activity19.10.2021 12:00:00 CEST | Press release
VANCOUVER, British Columbia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- FOBI AI Inc. (TSXV: FOBI) (OTCQB: FOBIF:) (the "Company" or "FOBI"), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement is pleased to provide shareholders with the following corporate update regarding the following significant company initiatives. COMPANY OPERATING FROM A POSITION OF STRENGTH AS A RESULT OF STRONGEST BALANCE SHEET TO DATE With the increased number of revenue announcements this past quarter, increased volumes and execution on key strategic acquisitions the company has experienced an increase in inquiries from new retail investors and especially from larger institutions. The momentum in revenue deals has increased with entry into new verticals such as Azincourt, Kiaro and Empower this past quarter. In addition, the company has benefited this past quarter from further warrant and option conversion totaling an additional $2,167,188 CAD. The